Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 183.81 Billion KRW | 17.23% |
| 2022 | 156.79 Billion KRW | 0.53% |
| 2021 | 155.97 Billion KRW | -0.46% |
| 2020 | 156.69 Billion KRW | 3.14% |
| 2019 | 151.92 Billion KRW | 9.59% |
| 2018 | 138.63 Billion KRW | 79.95% |
| 2017 | 77.03 Billion KRW | -42.4% |
| 2016 | 133.75 Billion KRW | -3.55% |
| 2015 | 138.68 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 43.84 Billion KRW | 5.11% |
| 2024 Q1 | 41.71 Billion KRW | -5.32% |
| 2023 FY | 183.81 Billion KRW | 17.23% |
| 2023 Q3 | 40.24 Billion KRW | -3.56% |
| 2023 Q2 | 41.72 Billion KRW | -28.11% |
| 2023 Q1 | 58.04 Billion KRW | 58.06% |
| 2023 Q4 | 44.06 Billion KRW | 9.49% |
| 2022 Q4 | 36.72 Billion KRW | -3.48% |
| 2022 Q1 | 39.99 Billion KRW | 5.8% |
| 2022 Q2 | 42.03 Billion KRW | 5.08% |
| 2022 FY | 156.79 Billion KRW | 0.53% |
| 2022 Q3 | 38.04 Billion KRW | -9.48% |
| 2021 Q4 | 37.8 Billion KRW | -3.23% |
| 2021 Q2 | 40.22 Billion KRW | 3.44% |
| 2021 Q1 | 38.88 Billion KRW | -5.37% |
| 2021 FY | 155.97 Billion KRW | -0.46% |
| 2021 Q3 | 39.06 Billion KRW | -2.88% |
| 2020 Q3 | 38.52 Billion KRW | -0.42% |
| 2020 Q1 | 38.38 Billion KRW | 2.84% |
| 2020 FY | 156.69 Billion KRW | 3.14% |
| 2020 Q4 | 41.08 Billion KRW | 6.65% |
| 2020 Q2 | 38.68 Billion KRW | 0.79% |
| 2019 FY | 151.92 Billion KRW | 9.59% |
| 2019 Q3 | 40.14 Billion KRW | 2.04% |
| 2019 Q2 | 39.33 Billion KRW | 12.02% |
| 2019 Q1 | 35.11 Billion KRW | -7.74% |
| 2019 Q4 | 37.32 Billion KRW | -7.01% |
| 2018 Q1 | 31.88 Billion KRW | -7.15% |
| 2018 FY | 138.63 Billion KRW | 79.95% |
| 2018 Q4 | 38.06 Billion KRW | 11.21% |
| 2018 Q3 | 34.22 Billion KRW | -0.67% |
| 2018 Q2 | 34.45 Billion KRW | 8.09% |
| 2017 Q2 | 10.59 Billion KRW | 0.0% |
| 2017 Q4 | 34.33 Billion KRW | 6.95% |
| 2017 FY | 77.03 Billion KRW | -42.4% |
| 2017 Q3 | 32.1 Billion KRW | 202.98% |
| 2016 FY | 133.75 Billion KRW | -3.55% |
| 2015 FY | 138.68 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -295.257% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 49.517% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 7.578% |
| HANDOK Inc. | 151.36 Billion KRW | -21.437% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -173.433% |
| Yuhan Corporation | 564.5 Billion KRW | 67.438% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 42.952% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -674.051% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 78.009% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -144.957% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 7.613% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -352.193% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -94.481% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -30.498% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -295.257% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -429.484% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -139.285% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 1625.987% |
| JW Holdings Corporation | 446.15 Billion KRW | 58.8% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 11.431% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 71.951% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 45.24% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -133.802% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -144.311% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -154.55% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -295.257% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 37.715% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 73.03% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 45.24% |
| Yuhan Corporation | 564.5 Billion KRW | 67.438% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 8.922% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -159.116% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -85.62% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 45.24% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -25.994% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -5.952% |
| CKD Bio Corp. | 5.01 Billion KRW | -3568.73% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 27.698% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 0.168% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -87.326% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -133.802% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 50.521% |
| Boryung Corporation | 333.26 Billion KRW | 44.845% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -267.295% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 7.613% |
| JW Lifescience Corporation | 51.32 Billion KRW | -258.138% |